MedTrace Logo

Venetoclax and Decitabine in R/R T-ALL

NCT06712121 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-02-02

No results posted yet for this study

Summary

The goal of this phase 2 clinical trial is to test the efficacy of decitabine and venetoclax combination chemotherapy in relapsed or refractory adult T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.

This study use a modified regimen of decitabine and venetoclax.

Conditions

  • T Lymphoblastic Leukemia/Lymphoma

Interventions

DRUG

decitabine plus venetoclax

decitabine 20mg/m2 for 7 days venetoclax 400mg daily for 21 days

Sponsors & Collaborators

  • Korean Society of Hematology

    collaborator NETWORK

  • Seoul National University Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-30
Primary Completion
2027-08-31
Completion
2028-08-31
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06712121 on ClinicalTrials.gov